Budget Impact Analysis for Semaglutide, Tirzepatide, and Dulaglutide for Type 2 Diabetes Mellitus Management in Saudi Arabia

Speaker(s)

Al-Omar H1, Almodaimegh H2, Omaer A3, Alzubaidi L4, Alharbi B5, Al harbi E6, Hassan M7, Akhtar O8
1College of Pharmacy, King Saud University, Riyadh, 01, Saudi Arabia, 2National Guard Health Affairs, Riyadh, Saudi Arabia, 3King Saud Medical City, Riyadh, Central, Saudi Arabia, 4Ministry of Health, Riyadh, Saudi Arabia, 5Prince Sultan Military Medical City, Riyadh, Saudi Arabia, 6Jeddah Military Hospital, Jeddah, Saudi Arabia, 7Novo Nordisk, Riyadh, Saudi Arabia, 8Poa Alpina Research, Seoul, Korea, Republic of (South)

Presentation Documents

OBJECTIVES: Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia resulting from insulin resistance and impaired insulin secretion, characterized by its chronic nature and accompanying risk of severe complications. Saudi Arabia has one of the most highly prevalent rates of T2DM in the world, ranking in the top ten globally. The management of T2DM has evolved to prioritize not only glycemic control but also weight management and cardiovascular risk reduction. The aim of this study is to estimate the budgetary impact of the three molecules in the management of T2DM considered as a set of separate scenarios reflecting procurement dynamics for the public-sector payer in Saudi Arabia.

METHODS: A budget impact analysis was developed from public payers perspective using real-world and clinical trials data. The model considered T2DM prevalence, medications prices, diabetes management expenses, cardiovascular complications costs, and weight reduction savings over a 5-year time horizon. To assess the robustness of the results, one-way sensitivity analysis (OWSA) was performed.

RESULTS: Over study period, the cumulative budget impact for semaglutide, tirzepatide, and dulaglutide were 85,923,089 USD, 169,790,195 USD, and 94,558,356 USD, respectively. Scenario analyses considering price parity between semaglutide and tirzepatide are associated with financial impacts of 85,923,091 USD and 86,475,335 USD, respectively. The OWSA suggested that the analysis was sensitive to price-per-pack, annual non-medication costs, proportion achieving HbA1c% target, incidence of non-fatal stroke, and hazard ratio of non-fatal stroke.

CONCLUSIONS: The findings suggested that injectable semaglutide may be a favorable choice for healthcare budget planners and decision-makers in Saudi Arabia for T2DM management. This suggestion should be balanced with supply and demand factors and molecules other approved indications.

Code

EE74

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Diabetes/Endocrine/Metabolic Disorders (including obesity)